CMS says Dendreon's (DNDN) Provenge Should be Covered (LINK)
Tweet
Share
E-mailGet Alerts DNDN Hot Sheet
Join SI Premium – FREE
More on CMS decision saying Dendreon Corp. (Nasdaq: DNDN) Provenge should be covered - Link to CMS decision
From the site:
The Centers for Medicare and Medicaid Services (CMS) has determined that the evidence is adequate to conclude that the use of autologous cellular immunotherapy treatment - sipuleucel-T; PROVENGE® improves health outcomes for Medicare beneficiaries with asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone refractory) prostate cancer, and thus is reasonable and necessary for that indication under 1862(a)(1)(A) of the Social Security Act (the Act).
From the site:
The Centers for Medicare and Medicaid Services (CMS) has determined that the evidence is adequate to conclude that the use of autologous cellular immunotherapy treatment - sipuleucel-T; PROVENGE® improves health outcomes for Medicare beneficiaries with asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone refractory) prostate cancer, and thus is reasonable and necessary for that indication under 1862(a)(1)(A) of the Social Security Act (the Act).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Regeneron's Pasatru for rare bone disorder FOP
- FDA grants fast track status to Rein Therapeutics drug for lung fibrosis
- AstraZeneca halts Phase III lung cancer trial after data review
Create E-mail Alert Related Categories
FDA, Hot FDA NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
